国际妇产科学杂志 ›› 2026, Vol. 53 ›› Issue (3): 297-301.doi: 10.12280/gjfckx.20251192

• 妇科肿瘤研究:综述 • 上一篇    下一篇

卵巢癌免疫微环境研究进展

武化拓, 黄春林, 马焱, 葛挺, 李莉()   

  1. 830000 新疆医科大学附属肿瘤医院(武化拓, 马焱葛挺,李莉);新疆大学(黄春林)
  • 收稿日期:2025-10-23 出版日期:2026-06-15 发布日期:2026-07-06
  • 通讯作者: 李莉 E-mail:donghui555@sina.com
  • 基金资助:
    科技创新领军人才项目-高层次领军人才(2022TSYCLJ0033)

Research Progress on the Immune Microenvironment of Ovarian Cancer

WU Hua-tuo, HUANG Chun-lin, MA Yan, GE Ting, LI Li()   

  1. Xinjiang Medical University Affiliated Tumor Hospital, Urumqi 830000, China (WU Hua-tuo, MA Yan, GE Ting, LI Li); Xinjiang University, Urumqi 830000, China (HUANG Chun-lin)
  • Received:2025-10-23 Published:2026-06-15 Online:2026-07-06
  • Contact: LI Li E-mail:donghui555@sina.com

摘要:

卵巢癌是女性生殖系统中致死率最高的恶性肿瘤。手术联合化疗是最主要治疗方案,但容易复发及产生铂类耐药。肿瘤免疫微环境在其发生发展、免疫逃逸及治疗抵抗中发挥关键作用。卵巢癌免疫微环境具有高度异质性,其细胞组成包括免疫细胞、基质细胞及异质性显著的恶性肿瘤细胞,不同细胞亚群通过复杂调控影响患者预后。主要的功能机制涉及程序性死亡受体1(programmed death-1,PD-1)与程序性死亡受体配体1(programmed death-ligand 1,PD-L1)等免疫逃逸关键通路、细胞因子/外泌体介导的细胞间通讯及微环境介导的治疗抵抗。目前研究技术有单细胞RNA测序、空间转录组等多组学技术与生物信息学分析,实验模型包括小鼠模型、患者来源异种移植模型及3D体外模型。靶向肿瘤免疫微环境的治疗策略主要有免疫检查点抑制剂、过继性细胞治疗及靶向免疫抑制细胞的干预手段,而联合治疗更具应用前景。未来研究需聚焦多层次数据整合、新型多靶点治疗策略开发及个体化治疗模式推进,以期为卵巢癌患者提供更有效的治疗方案。

关键词: 卵巢肿瘤, 癌, 肿瘤免疫微环境, 肿瘤逃逸, 免疫疗法, 分子靶向治疗

Abstract:

Ovarian cancer is the malignancy with the highest mortality rate in the female reproductive system. Surgery combined with chemotherapy is the primary therapeutic regimen, but the disease is prone to recurrence and the development of platinum resistance. The tumor immune microenvironment plays a crucial role in its pathogenesis, immune evasion, and therapeutic resistance. The immune microenvironment of ovarian cancer is highly heterogeneous, comprising immune cells, stromal cells, and significantly heterogeneous malignant tumor cells. Different cellular subpopulations influence patient prognosis through complex regulatory mechanisms. Key functional mechanisms involve critical immune evasion pathways such as the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) axis, as well as cytokine/exosome-mediated intercellular communication, and microenvironment-mediated therapeutic resistance. Current research techniques include single-cell RNA sequencing, spatial transcriptomics, and other multi-omics technologies combined with bioinformatics analysis. Experimental models include murine models, patient-derived xenograft models, and three-dimensional (3D) in vitro models. Therapeutic strategies targeting the tumor immune microenvironment primarily involve immune checkpoint inhibitors, adoptive cell therapy, and interventions targeting immunosuppressive cells. Combination therapies show greater potential for clinical application. Future research should focus on integrating multi-level data, developing novel multi-target therapeutic strategies, and advancing personalized treatment approaches to provide more effective therapeutic options for patients with ovarian cancer.

Key words: Ovarian neoplasms, Carcinoma, Tumor immune microenvironment, Tumor escape, Immunotherapy, Molecular targeted therapy